We are developing urine-based assays to detect mutations or signature profiles implicated in many types of cancer. These assays may prove extremely useful as an aid in the personalized management of patient care in various types of cancer, including colorectal, lung and pancreatic. These tests are ideal in circumstances where regular monitoring is recommended, including treatment response, non-response, disease recurrence and detection of resistance markers.
Current assays in development include EGFR, NRAS and PIK3CA. These mutations have a broad applicability across numerous cancers. For T790M and NRAS, there are several targeted therapies in development where treatment response or non-response is dependent upon the presence or absence of these mutations in primary or metastatic cancers.
Specific tests planned for development during 2014 include: